Omnicell (OMCL) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- —
- Estimate
- $0.42
- Surprise
- —
- Score today
- 5.7/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
Coverage in the report window
- Omnicell Sees Q4 Adj EPS $0.41-$0.49 vs $0.37 Est; Sees Sales $295.000M-$301.000M vs $310.442M Est — benzinga, 2026-10-29
- Omnicell Raises FY2026 Adj EPS Guidance from $2.15-$2.30 to $2.48-$2.56 vs $2.27 Est; Narrows FY2026 Sales Guidance from — benzinga, 2026-10-29
- Omnicell Q3 Adj. EPS $0.58 Beats $0.42 Estimate, Sales $307.851M Beat $304.474M Estimate — benzinga, 2026-10-29
Where TrendMatrix's rating stands now
TrendMatrix currently rates OMCL Hold at 5.7/10; no pre/post engine snapshot brackets this report.
2 of the last 4 quarters beat the estimate.
What supports the rating
- Sector modifier (Healthcare): +0.5
- Analyst upside: 40%
What argues against it
- V7 low-quality RISK_OFF penalty: -0.5 (Q=4.8)
- Below 200-MA, MA slope -3.5%/30d (confirmed downtrend)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $35.95
- Price target
- $50.34
- Stop
- $33.43
- Upside to target
- +40.0%
- Reward-to-risk
- 5.0:1
The stock trades at 42.8× trailing but 17.5× forward earnings — consensus estimates already build in a substantial earnings recovery.
Risk check: trading volume is running 1.9× its average — elevated turnover around the report window.
Model outputs from TrendMatrix’s engine as of 2026-10-29 — shown for context, not personalized investment advice.
OMCL at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Health Information Services
- Market cap
- $1.64B
- P/E (fwd)
- 17.5
- P/E (ttm)
- 42.8
- 52-week range
- $29.09–$55.00
- Off 52-week high
- 34.6%
- RSI (14)
- 56
- Volume vs avg
- 1.90×
- Score today
- 5.7/10